Related Experiment Video
Updated: Jan 10, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
Mechanisms of metabolic transition in hypertrophic cardiomyopathy
Conghao Tan1, Zhexuan Guo1, Junjie Zhou1
1Department of Cardiovascular Medicine, Zhenjiang First People's Hospital, Zhenjiang, Jiangsu, China.
Insights
Hypertrophic cardiomyopathy (HCM) involves altered cardiac cell metabolism. Understanding this metabolic transition is key to developing new diagnostic and treatment strategies for this heart disease.
Area of Science:
- Cardiology
- Biochemistry
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with significant global health impact.
- Current treatments improve prognosis but do not fully address the disease burden.
- Metabolic transition in cardiac cells is increasingly recognized as a critical factor in HCM progression.
Purpose of the Study:
- To elucidate the role of metabolic transition in the pathogenesis of Hypertrophic cardiomyopathy.
- To identify potential therapeutic targets by understanding altered metabolic pathways in HCM.
Main Methods:
- Review and synthesis of current research on metabolic alterations in HCM.
- Analysis of changes in glucose, lipid, and amino acid metabolism in cardiomyocytes.
- Correlation of metabolic shifts with clinical manifestations like fibrosis and diastolic dysfunction.
Main Results:
- HCM hearts show increased reliance on glycolysis and impaired aerobic glucose oxidation.
- Defects in fatty acid beta-oxidation lead to lipid accumulation (ceramides, sphingomyelins).
- Altered amino acid metabolism, including elevated branched-chain amino acids, is linked to cardiac remodeling and insulin resistance.
Conclusions:
- Metabolic transition, encompassing shifts in glucose, lipid, and amino acid pathways, is central to HCM pathogenesis.
- Understanding these metabolic changes is crucial for developing novel diagnostic and therapeutic strategies for HCM.
- Targeting metabolic pathways may improve patient outcomes and quality of life in Hypertrophic cardiomyopathy.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a prevalent hereditary cardiovascular disease that affects individuals worldwide. While current treatments have improved the prognosis for many patients, HCM continues to impose a significant burden on global healthcare systems. Understanding its underlying mechanisms, particularly the role of metabolic transition, is crucial for enhancing diagnosis and treatment strategies. One of the most promising areas of research in HCM is the study of metabolic transition. This process, which involves significant changes in energy production and consumption within cardiac cells, has become increasingly recognized as a key factor in the disease's progression. In HCM, glucose metabolism is markedly altered. The heart increasingly relies on glycolysis for energy production, while the aerobic oxidation of glucose is impaired. These changes are accompanied by alterations in the activity of glucose transporter proteins and key enzymes involved in glycolysis. Such abnormalities are closely associated with myocardial ischemia, fibrosis, and an increased risk of acidosis in cardiomyocytes, which in turn affects calcium cycling and cardiac diastolic function. Lipid metabolism is significantly altered in HCM. There is a defect in fatty acid β-oxidation, leading to the accumulation of ceramides and sphingomyelins in cardiomyocytes. Additionally, changes in ketone body metabolism occur as an adaptive response to energy deficiency, which may further affect cardiac function. Amino acid metabolism is also altered in HCM. Elevated levels of branched-chain amino acids have been observed, and these metabolites are strongly associated with cardiac remodeling and the development of insulin resistance. These changes further contribute to the maladaptive processes in HCM. A comprehensive understanding of the metabolic transition process in HCM is essential for unraveling the disease's pathogenesis. Such insights could pave the way for novel therapeutic strategies, ultimately improving patient outcomes and quality of life.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy V: Interprofessional Care
Pathophysiology of Heart Failure
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy

